Curaleaf Holdings, Inc. (CURLF)
| Previous close | 5.50 |
| Open | 5.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.16 - 5.65 |
| 52-week range | 2.36 - 6.40 |
| Volume | |
| Avg. volume | 845,038 |
| Market cap | 4.024B |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.32 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.49 |
PR NewswireCuraleaf Reports First Quarter 2024 Results
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2024. All financial information is reported in accordance with U.S. generally accepted accounting principles (GAAP) and is provided in U.S. dollars unless otherwise indicated.
Yahoo FinanceWhat marijuana reclassification means for the US cannabis industry
Curaleaf CEO Matt Darin said it was "a historic moment" for the cannabis industry following reports that the DEA is seeking to reschedule marijuana. Here are some of the implications for the weed industry.
- Yahoo Finance Video
DEA's reclassifying marijuana sends signal to DC: Curaleaf CEO
Drug Enforcement Administration (DEA) officials have proposed reclassifying marijuana (or cannabis) as a Schedule Three drug. Despite a majority of states having legislation allowing for medicinal and recreational use, marijuana it still classified as a Schedule One narcotic along with heroin. Curaleaf (CURLF) CEO Matt Darin sits down with Catalysts Hosts Seana Smith and Madison Mills to talk about how long cannabis businesses has been waiting for a change like this and what it signifies for the future of the industry and the SAFE Banking Act. "It's a long time coming, but I think the findings are really backed in science and backed under a very detailed review that the government did to evaluate the medicinal benefits of cannabis," Darin says, "and that it truly does belong as a Schedule Three, a substance versus Schedule One on par with things like heroin and fentanyl which all Americans have known for quite some time, just was not right." For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Luke Carberry Mogan.
